November 3, 2026 29 min read

Pfizer (PFE) — Q3 FY2026 Analyst Q&A Breakdown

Fiscal period: Q3 FY2026 · Report date: November 3, 2026

Eleven analysts took the queue on the November 3, 2026 call, including three congratulatory threads for new CFO Cecile Guegan. The exchanges below cover every question turn — the transcript’s own garbled drug and program names are rendered through the canonical names established in this report set (berobenatide, telrecomec, MEVPRO-1/2/3 with agent meprometastat, semaglutide as Wegovy, PADCEV, NURTEC, Metsera, MFP), and quotes keep the tape’s exact wording. Figures first offered by an analyst are labeled analyst-provided; where management confirmed, disputed, or passed on them, the response says which.

Q1 — Chris Schott, JP Morgan (single turn, both parts (a)/(b) together)

The Question: Two pipeline asks. (a) Positioning of the trispecific telrecomec (the transcript garbles the name as “Tareqa, Meg”) in atopic dermatitis — how to think about first-line versus second-line use “as we consider… the very strong data you presented versus a very well-entrenched standard of care” (analyst framing), plus timelines for indications beyond AD. (b) Expectations for “the upcoming Phase 1/2a amylin and combo data” — “and then the type of titration schedule that’s being used in that study just to help us frame out what we’re going to see with that, with that readout.”
Management’s Response: Albert Bourla routed (a)-timelines plus the amylin piece to Chris Boshoff. On telrecomec: the Phase 3 atopic-dermatitis program has started — “2 studies. One of those studies include a head-to-head against dupilumab” — with a Phase 2/3 continuum design for COPD and Phase 3 severe asthma started, readouts expected in 2028 and 2029. On amylin: SOLIS-1 “has now completely recruited — that is the robustly designed Phase 2b study for amylin single agent and amylin plus berabinitide [garble of berobenatide] in different doses and different titrations,” with the efficacy readout in the second half of 2027; the ongoing Phase 1/2a gets an update at the end of this year, “recognizing that study was designed for safety and PK clinical pharmacology, not for efficacy.” The positioning half of (a) went unanswered by R&D and was re-opened by the CEO as a separate turn (Q2).
The “Analyst’s Take”: Direct on every timeline Schott named, but silent on both things he actually asked to frame the data — positioning and titration mechanics — and management gave neither beyond “different doses and different titrations.” The load-bearing line is the expectation-setter: the Phase 1/2a “was designed for safety and PK clinical pharmacology, not for efficacy” — a falsifiable commit to an end-2026 update carrying no efficacy claims.

Q2 — Albert Bourla, Chairman & CEO (separate follow-up turn re-opening Schott’s positioning half)

The Question: “And then what about the positioning of the trispecifics? How do you think about that?” — routing the commercial question away from R&D.
Management’s Response: Alexandre de Germay took it, anchor on the derm franchise. The category is “very large,” and “what we have learned with our Cibinqo [transcript: Cibinco] and overall dermatology franchise is there is a lot of patients profile that requires different type of therapy” — JAK versus mAb, with patients dropping off and circulating between the two modalities. Capabilities are being built across US and international. The new number: “in international, we reached like $100 million combined between our 2 assets in dermatology for the quarter” (management-disclosed), a base to capture “lapsed patients and naive patients with a very specific profile that we are defining — so first in class, strong efficacy, and clearly unmet medical need.”
The “Analyst’s Take”: A real deliverable emerged — the first dermatology revenue baseline any Pfizer prescription says out loud — but positioning versus the “well-entrenched standard of care” stays profile-based and pre-readout: lapsed/naive capture is a strategy for after the data, not a first-line claim today.

Q3 — David Risinger, Leerink Partners

The Question: Opened with congratulations to Cecile Guegan on her new role. Asked on US net price “in the 3rd quarter and going forward”: any gross-to-net benefits to net sales in the quarter, “including from any 340B scrubbing,” and near-term US net-price prospects.
Management’s Response: Cecile Guegan kept Q3 clean: with one exception, “there is not really any very material change into our gross-to-net dynamics during the 3rd quarter” — the exception being, as expected, “the impact on Eliquis, which started in Q3, of the January 1 price decrease.” Quarter performance is “for the most part driven by strong market performance and volume rather than dynamics around the gross-to-net.” She then declined forward numbers: “obviously I’m not commenting today on 2027,” though guidance will reflect the IRA with “2 of our products entering the MFP in 2027” (the tape renders MFP as “MFE”), the 340B changes “including the credit rebate model implemented starting in January,” and MFN impacts “following the agreement we have with the government.” Summary: Q3 was “really a reflection of the strong execution rather than dynamics around gross-to-net.”
The “Analyst’s Take”: Direct where it counts — a dated, checkable event (the January 1 Eliquis decrease landing in Q3) — and disciplined on the future: a stated sequencing decision, not evasion. But the 340B half of the question fell away: no scrubbing was quantified, and the 2027 stack was named, not weighed.

Q4 — Umar Rafat, Evercore ISI

The Question: Acknowledged SG&A progress as “not step function” but recalled (analyst-provided) that Dave — the outgoing CFO “before he moved on” — “had mentioned that majority of the total net cost savings of $7.2 billion will be delivered by the end of ‘26.” His analyst-provided arithmetic: SG&A plus R&D “was about $24.5 billion back in 2022. It’s about the same in 2026 as well,” OpEx still “broadly in that $24 to $25 billion camp.” If savings are real, where is the cost lever “heading into the dividend integrity… heading into patent expiries”?
Management’s Response: Cecile Guegan confirmed the savings ledger and reframed the arithmetic rather than disputing it: “we are on track to delivering to $7.2 billion of savings” from phase 1 — with the composition explaining the flat OpEx the analyst saw: one, “in our manufacturing footprint or cost”; two, “in R&D, but reinvested. And we are indeed increasing our R&D investment”; and on the SG&A side, “mostly coming from the commercial and marketing expenses as well as [G&A].” Q3 itself “had some one-time dynamics that drove the [SG&A] up,” while FY26 guidance still expects “a decline in SG&A versus last year.” Forward lever, stated: the announced second phase with $2.5 billion of savings in both SG&A and manufacturing costs, “translating and mitigating the margin erosion as part of the LOE transition in 2027 to 2029.”
The “Analyst’s Take”: The answer explains why the analyst’s $24–25B number does not shrink (a savings-mix answer: manufacturing dollars and R&D reinvestment do not show as OpEx decline) and answers the forward question with a 2027–2029 margin-erosion mitigant. Direct, but the terminal year still has no OpEx level promised — only a direction for FY26 SG&A.

Q5 — Akash Tiwari, Jefferies (single turn, both parts (a)/(b) together)

The Question: (a) STAT6: recalled (analyst-provided) that “in the spring you had a kind of 4,550-patient biomarker analysis on your STAT6” feeding a decision on whether to go from stage 1 to stage 2 — any update? And “how do you think about TARC reduction and biomarker reduction to what we’ve seen with some of the degraders” (analyst-supplied comparator context). (b) “On your GLP-1 AMLN, I think your phase 1/2, you just updated on ClinTrials to 201 patients. I think it was originally planned to be closer to 400” (both counts analyst-provided) — “Any color on what drove that decision with the amylin GLP-1 combo with Mithsara?” (transcript garble).
Management’s Response: Chris Boshoff on STAT6: “potentially first-in-class,” important for the inflammation & immunology (the tape says “INI”) portfolio, and — matching what the analyst recalled — “we’ve adapted the program to incorporate some additional DDI studies. So we should give you a readout for the statistics later this year” (the tape’s “statistics” is the STAT6 garble). No stage-decision disclosure, and the TARC-versus-degraders comparison was not taken up. On the amylin numbers: SOLIS-1 is fully recruited with its efficacy readout “end of next year,” and the Phase 1/2a shrink is explained as design, not economics: “the Phase 1/2a study was adapted for the additional PK studies we are doing. But there’s nothing really… material changed to the trial” — with the 201-versus-~400 counts neither confirmed nor disputed.
The “Analyst’s Take”: Half a direct answer. The part answered is a commit with a date (STAT6 readout later this year, after added DDI studies); the part passed is the biomarker-vs-degraders question, and the enrollment answer offers a cause without a bar for whether the 400-patient power was ever the plan.

Q6 — Vamil Divan, Guggenheim (single turn, both parts (a)/(b) together)

The Question: (a) Analyst-provided observation that Pfizer “posted a new Phase 1 trial for your PI3K inhibitor on ct.gov last week,” with reference to management’s earlier comments “around a tirmociclib and your CAT6” (transcript garbles of covered assets — the CDK4 inhibitor atemaciclib and the KAT6 inhibitor provetristat): how does the PI3K asset fit the broader breast-cancer strategy? (b) The VOLGA data “that AstraZeneca released” at ESMO (analyst-provided), which “could suggest maybe less need for… the use of fewer cycles of PADCEV in patients… with bladder cancer” — reaction and how it may play out.
Management’s Response: Chris Boshoff on (a): the new Phase 1 is “on an internally discovered PIK3CA inhibitor,” with the reminder that gedatolisib (the tape garbles “gedatolacib with selcuety”) “is also Pfizer-discovered medicine,” and an ongoing “Relay” trial running the pan-alpha isoform-selective PIK3CA inhibitor zovigalacib. The atemaciclib hook is combination cleanliness: “the advantage of atemaciclib is we do not see DDIs, which has been experienced with all the other CDK4/6 inhibitors combining with the PIK3CA… it’s a potentially significant advantage.” Prevalence stakes: “up to 40% of breast cancer, ER-positive breast cancer, up to 20, 25% of HER2-positive breast cancer will harbor a PIK3CA mutation.” On (b), “the VALGAR data” (his own re-garble of VOLGA): the read “reinforces the use of PADCEV for muscle invasive bladder cancer” and “PADCEV in combination with the PD-1,” and “reinforces the confidence we have” in study 309 (bladder-sparing PADCEV + pembrolizumab, just started) and in the planned Phase 3 of PADCEV plus tevonatamab starting later this year. Then the caveats he added voluntarily: “this was a no-cisplatin eligible population. Pathological complete remission was lower than what we’ve seen with pembro plus PADCEV, which is important, including slightly lower event-free survival” — and, in the curative-intent setting, “we’re not clear yet which patients can be de-escalated.”
The “Analyst’s Take”: A competitor dataset was met with a reaffirmation plus two trial starts it supposedly supports — but the distinguishing answer is the caveat stack he volunteered, which quietly contests the de-escalation thesis the question was built on. Direct, and neither defensive nor dismissive.

Q7 — Evan Seigerman, BMO Capital Markets

The Question: To the new CFO: “Did you inherit the capital allocation framework kind of established by your predecessor?” And the marginal-dollar menu: internal R&D, “another bolt-on you talked about, BD capacity, deleveraging, and eventually restarting buybacks” — “where do you currently see the highest prospective return for shareholders?”
Management’s Response: Cecile Guegan: continuity over authorship. “Our priorities are clear and they are not changing versus what was in place,” with a “solid plan to get us through LOE and post-LOE.” The priorities: “invest for growth, maintain or grow our dividend over time, and then keep a strong balance sheet.” Through the LOE period, “our operating cash flow, financial assets, and access to capital markets will give us the ability to continue to invest and maintain the dividend.” Post-LOE, “our operating cash flow grows with the levers,” and “share repurchases become again one of the levers” to enhance shareholder value. She did not rank the marginal-dollar menu.
The “Analyst’s Take”: The interesting word is again: repurchases are framed as a resumed lever, not a live one — the buyback stays parked until operating cash flow grows post-LOE, which is the closest thing to an answer on sequencing without a ranking. On inheritance, “not changing versus what was in place” is continuity asserted while sidestepping the predecessor framing.

Q8 — Steve Scala, TD Cowen (single turn, both parts (a)/(b) together)

The Question: (a) “Given the pushout of MEVPRO1 [the analyst’s own framing, implying a slip], were there any changes to MEVPRO2 and 3 timelines?” (b) For Cecile, an analyst-provided career narrative: “you started at Pfizer when Warner Lambert was being consolidated, have been through the acquisitions of Pharmacia, Wyeth, and C. Gen. [garbled name], and many BD deals, including that for Eliquis.” The thesis: “it could be argued that Pfizer’s most successful products have come through deals. And in each of those years, as it is now, Pfizer viewed its pipeline as very good.” So why doesn’t Pfizer make another big deal its primary focus — or would she say the pipeline is “significantly better now than at any time in the last 25 years”?
Management’s Response: Bourla handed (b) to Cecile Guegan, who opened with a premise correction — the exchange’s centerpiece: “just for the record, I came with Wyeth and not [Warner Lambert].” Without the full deal history she still ranked the tape-garbled “YSA” [Wyeth] admission: “I think [Wyeth] was one of the best acquisitions that we did,” sees “a transformation of Pfizer and a strengthening definitely of our pipeline over the last 25 years,” and contested the “pipeline was always this good” frame. The big-deal answer is built on executed transactions already “driving success — we’re talking about PADCEV [tape: Patsyf], we’re talking about NURTEC [tape: Nartech],” with “a lot of opportunities that still remains in the pipeline in Seagen, in Metsera [tape: Medcera]” to execute “both commercially and on an R&D side.” Going forward, “our focus is really on more bolt-on acquisitions that are going to complement the large and rich portfolio that we have in the 4 therapeutic areas” — strategically aligned, building on expertise, with “appropriate returns.” The MEVPRO part was handed to the CEO’s follow-up turn (Q9).
The “Analyst’s Take”: The premise correction is the only on-record biographical fact of the call’s new-CFO era, and it punctures the question’s architecture before answering it. The substance is a clean two-stroke: today’s growth sellers (PADCEV, NURTEC) were yesterday’s big deals, and tomorrow’s BD is bolt-ons only — direct, with the pipeline-better-now half conceded affirmatively.

Q9 — Albert Bourla, Chairman & CEO (separate follow-up turn: “Chris, you want to comment a little bit on the timelines of Mevro [garble]? And given the interest in the product, maybe Aamir, also you say a few things about the potential.”)

The Question: The MEVPRO timelines Scala asked in Q8(a), re-dispatched — the second CEO turn explicitly completes the routing: “And Aamir, why are we so excited about MEVRO in terms of the commercial opportunity?”
Management’s Response: Chris Boshoff led with process, not defense: “Since we last spoke about it, the timelines have been updated for METRO-1 and METRO-2 [transcript spellings]. A reminder, these are event-driven studies, so it’s based on when we expect events to happen. So METRO-1 will now read out Q1 2027 and METRO-2 Q3 2027” — then, in the same breath, the correction: “just to correct, MEVRO-2 is actually Q4 2027, the updated in clinicaltrials.gov.” ESMO showed “additional data including compelling… 8.9 months PFS.” Albert Bourla’s add (no ask pending): “I think MEVRO-1 you expect around February?” — Chris: “February, correct” (that check is its own unit, Q10) — and the projection rests on “the way that events are accruing.” Aamir Malik gave the commercial case in three strokes: the current prostate franchise footprint is US-anchored “alongside Astellas,” while this asset is “a fully global opportunity in the U.S. and outside the U.S.”; across MEVPRO 1, 2, and 3 the potential is “a multi-indication franchise,” giving “lots of surface area to compete”; and the patient math is management-disclosed — “over 50,000 in the U.S., close to 50,000 in the EU4 and UK, another 14,000 in Japan,” with “~30% of that population could be addressed even with MEVPRO1.” Bourla’s kicker: “sometimes people forget that Xtandi… we basically have half of the Xtandi in the US and that’s it. Here we are going to have the whole US and the whole global international market.” MEVPRO-3 was left undated.
The “Analyst’s Take”: The transcript’s most candid data moment — a quarter stated and retracted inside one answer, against the public trial registry. Aamir’s answer converts the timeline question into a value case with four checkable numbers, and the Astellas contrast is the soundest framing on the call. Only the third trial stays undated.

Q10 — Albert Bourla / Chris Boshoff (separate clarification turn inside the Q9 thread)

The Question: “I think MEVRO-1 you expect around February? Around” — a two-way confirmation on the Q1-2027 readout’s position inside the quarter.
Management’s Response: “February, correct.” Bourla’s framing: “This is the projections right now based on the way that events are accruing.”
The “Analyst’s Take”: Nothing travels further in a two-word unit: February becomes the planning anchor for the quarter the prepared remarks only gave as “Q1 2027, based on the current event rate.” Falsifiable by clinicaltrials.gov’s next update.

Q11 — Geoff Meacham, Citibank (operator label; the speaker block reads “Geoff Meacham”) (single turn, both parts (a)/(b) together)

The Question: (a) To Albert on policy, “especially given today” (US election day): looking to 2027, “what are your thoughts on the potential risks of changes to MFN? Or perhaps greater scrutiny on the prior OUS agreements?” (b) For Chris on berobenatide (transcript garble “baribinitide”): “You guys have started a lot of studies across metabolic indications and beyond obesity, diabetes” — thoughts on expanding “as a combo strategy into inflammation or neuropsych or even oncology, for example, that obviously the science is really evolving here on the GLP-1 synergies.”
Management’s Response: Albert Bourla on (a): “clearly policy affects a lot our industry, and we are monitoring it very carefully. We are waiting to see what will happen today in the elections. But I think that in any case, it looks like we will have a split government. Expect policy changes, frankly.” The contrast he draws is to a year ago: “In 2025, I was really scared about the implications that either tariffs or MFN could have. I think through the successful navigation of those issues, we brought the stability that it is now projected to last” — the confidence of sector investors back as the result. Scrutiny of prior OUS agreements went unaddressed. Chris Boshoff on (b): the obesity goal stands first — “our goal is initially to establish berobenatide [tape: beraubenatide] as a potentially best-in-class monthly subcutaneous GLP-1 for obesity. And this is globally” — with new studies starting now in knee osteoarthritis and obstructive sleep apnea “with or without PAP,” “additional phase 3 studies in the coming months,” and in 2027 “we hope to announce some additional studies looking at the backbone of our portfolio, including Ionide [transcript garble], potentially in oncology,” plus “the acceleration of phase 1 programs and current programs that’s preclinically, that’s highly differentiated in this space.”
The “Analyst’s Take”: The policy answer is a regime-certainty claim — split government named, changes expected, 2025’s fear reinterpreted as the process that produced durable stability — thin on the OUS-agreements half. The combo answer is a roadmap with no 2027 named asset: “Ionide” stays a garble, and inflammation/neuropsych get no commitment beyond “oncology, potentially.”

Q12 — Alex Hammond, Wolfe Research (single turn, both parts (a)/(b) together; the internal clarification that follows is unit Q13)

The Question: (a) “As you look at Sciwen Biosciences’ GLP-1 launch in China [transcript garble — the exchange makes clear he means the company’s own semaglutide (Wegovy) launch], how are both the obesity and the diabetes markets playing out so far, and how is that shaping your thoughts on the commercial opportunity for berobenatide OUS [transcript: verobenatide]?” (b) “On the Lyme disease vaccine, can you update us on the regulatory path forward following the recent submission in Europe. How are your discussions with FDA progressing, and are there any meaningful differences between the FDA and EMA?”
Management’s Response: Alexandre de Germay took (a) at depth — this was the call’s densest commercial answer. Introductions: “we’ve introduced semaglutide [tape: secaglutide] in China at the end of April of this year, and we are satisfied with the way we are progressing,” with “a lot… learned through the launch of Wegovy in China.” The market splits itself: chronic-weight-management patients all share the classification but split into “some of them have more of an aesthetic-driven purpose” and, on the opposite side, “very heavy people looking for much more efficacy, tolerability” — different products, different acquisition channels. So the strategy confirmation: “if we want to be successful in chronic weight management, you need to have a portfolio,” because “you will need to activate all those different channels, and the cost of activations of those channels will be amortized across the portfolio.” Wegovy-specific progress, dated twice: with T2D approval in hand “since the end of October” — which “opened up the hospital channel… it also opened up for local regulations the e-commerce channels” — and acknowledgment that “our competitors have also access to reimbursements, and this is very important to compete effectively”: “since June, we passed the NRDL committees, and now we’re expecting the final review by the end of this month,” so the two together “will really be the start of penetration of the market.” Bourla then generalized the model: obesity recalls “the times of the Viagra launch” — “people are willing to pay out of pocket for products that they value, irrelevant if they are reimbursed or not,” which “creates dramatically different size in the international markets” — e-commerce pivotal, Pfizer’s existing consumer flow (vaccines, Paxlovid, migraine products) already moving “through the Pfizer for All” channel (“our consumer, let’s say, web port”), and “AI is changing the way that promotions are happening right now… even more importantly at the patient’s level.”

The (b) exchange then ran as a chain of three managers under the recovered Lyme dispatch (Q13). Chris Boshoff gave the program status, all of it new relative to the prepared remarks: “the burden of the disease is increasing globally. The EMA has validated the MAA [the tape’s “MRA”] for Pfizer and Valneva’s Lyme disease vaccine candidate with the validation, and the CHMP will now begin its assessment of the MAA, and the CHMP is expected to issue an opinion on… marketing authorization 2027.” Plus a second filing now in hand: “we’ve also now filed in Canada, and we continue our discussions with the FDA and should provide an update regarding this in Q4… in Q4 of this year.” The FDA-versus-EMA-differences ask went unenumerated. Alexandre de Germay added the commercial playbook on record: “we already have an FSME franchise in Europe, and we know how to activate tick-borne populations in those endemic areas because we have a sales force, we have a commercial play with pharmacies,” the population’s awareness “significantly higher than what we have in FSME,” and — the line that names the asset — “as we have built these muscles commercially, once we have the approval, we’re very much looking forward for the opportunity to commercialize this vaccine.” Bourla closed the US frame: US disease awareness is “skyrocketing right now because we do have an increase of severity and incidence,” and “we are looking forward to concluding the discussions with FDA and submitting our file.”

The “Analyst’s Take”: (a) was answered to its widest form — a working theory of Chinese weight-management markets, two dated regulatory wins, a competitor parity admission on reimbursement — but berobenatide-OUS itself only got indirect treatment: the portfolio thesis is stated “confirm[ing] our strategy,” with no OUS launch plan for Pfizer’s own asset. (b) delivered an enumeratable regulatory state (MAA validated, CHMP opinion in 2027, Canada filed, Q4-2026 FDA update promised) while the comparison question — meaningful FDA/EMA differences — was passed over entirely.

Q13 — Albert Bourla / Chris Boshoff (separate clarification turn inside Hammond’s Q12 thread)

The Question: Bourla, after he first took the floor unprepared: “I’m not sure I understood the second question.”
Management’s Response: Chris Boshoff supplied the referent — “Lyme disease, Lyme vaccine” — and Bourla recovered with “Ah, the Lyme vaccine. Okay, yes” before dispatching (see Q12’s Lyme handling below).
The “Analyst’s Take”: A rendering-conscious unit: without Chris’s prompt, the Lyme half of Hammond’s question would have been lost to the CEO’s reframe of (a). The recovery is immediate, and the exchange underscores how far the Lyme program travels on spoken tradition rather than prepared text.

Q14 — Michael Yee, UBS (single turn, both parts (a)/(b) together)

The Question: (a) “On MEVPRO, you guys continue to be pretty bullish. I know there was a formulation change to lower the Cmax and improve the tolerability” (analyst-cited formulation premise, management-corroborated). “Maybe you could comment on how you feel about dropouts and the change in formulation to drive your effect?” (b) Transcript mislabel alert: “on teclistamab, your trispecific, again, something you’re pretty bullish on” — teclistamab is a Johnson & Johnson-marketed bispecific, not a Pfizer asset; the “your trispecific” framing and the context point unambiguously to Pfizer’s IL-4/IL-13/TSLP trispecific telrecomec from the prepared remarks, and Boshoff’s answer re-keys it as “telrigamicab” (garble). The ask: “Can you just comment on neutralizing antibodies or ADAs, things that can be tricky for bispecifics and trispecifics and how you feel about that?”
Management’s Response: Chris Boshoff on (a): the Phase 3 was “adapted to have a more tolerable dose with… food where we decrease the… Cmax but see… similar AUC to what we’ve seen in Phase 1. So we’re very confident in the PK data and the… dose that was selected for the Phase 3 study” — the dropouts half went unaddressed. On (b): “we have not seen functional neutralizing antibodies or functional ADAs… Thus far, you’re absolutely correct. For any bispecific or trispecific, that’s a long-term risk.” But followed-through: “so far, we haven’t seen anything impacting efficacy. And in fact, longer-term follow-up on the studies we previously demonstrated or showed show us that we do not have an impact on efficacy.” Bourla’s sign-off carried the tone of the hour: “Let’s keep it that way if you can, please.”
The “Analyst’s Take”: A clean risk-and-record answer: the class risk conceded in principle, the trial record claimed clean on both ADA and efficacy. The dropout question disappeared, and nothing in the answer quantifies follow-up duration — the “longer-term follow-up” claim is unusually specific without being datable. The drug-name confusion is a transcription artifact worth flagging, not a management error.

Q15 — Asad Haider, Goldman Sachs (single turn, both parts (a)/(b) together; final analyst of the call)

The Question: Congratulated Cecile again. (a) On 2027, “appreciate the context provided earlier on price dynamics with respect to IRA and 340B” — “any additional high-level qualitative framing on other pushes and pulls next year to be aware of ahead of formal guidance?” Plus a benchmark question: “how should we be thinking about your guidance philosophy relative to Dave’s [predecessor], broadly speaking?” (b) Long-term: “you are reiterating line of sight to high single-digit revenue CAGR towards the end of the decade off of a 2028 base, as well as citing operating leverage and margin expansion given the cost realignment initiatives. But consensus numbers are not really modeling that. There does seem to be a disconnect on both revenue and the earnings lines versus your own expectations. So as you examined Street forecasts, what are the key assumptions that you think are getting most mismodeled in the P&L relative to your own internal expectations as you look out towards that period?”
Management’s Response: Cecile Guegan dated the deliverable first: “we’ll provide [2027] guidance around middle of December like we did last year” (the tape runs “2023 2027 together” — a garble of 2027 guidance), so only “high-level key drivers” now. The drivers, in her order: the LOE impact — “not only in the US with Ibrance and Xtandi and some other products, but also in international where we are seeing Eliquis being LOE at the end of 2026”; the offset — “the ramp-up of our launched and acquired portfolio, which again, as you have seen, is having a very strong performance and still opportunity for growth,” including new indications on those products; “obviously pricing, including MFN and RORAs [transcript garble], which we will reflect in our guidance”; and the cost initiative program — “continue to… invest towards the growth opportunities… on the [SG&A] marketing and commercial space, and then increase the productivity and deliver savings both on the commercial spend and as well on the general and administrative spend.” The guidance-philosophy-vs-Dave question was not taken up. On (b), her frame: “if you look at where that difference is coming from, it’s not really coming from one place on one product. And so is our growth trajectory either.” The building blocks: continued growth of the launched-and-acquired products — market growth, rising penetration — “but also on top of it, we are bringing new indications onto those products”; and the pipeline: “obesity being one, some of the oncology products being one” as the clear company-view-versus-Street-view differences, with the commitment that “our growth trajectory doesn’t rely on one single product or one single therapeutic area,” backed by “several Phase 3 ongoing as well as upcoming catalysts over the 18 to 24 months” that “should give confidence to the outside world.”
Management’s Response (Bourla’s closing addendum): Albert Bourla took the Street question head-on and made it the call’s coda: the internal-versus-Street gap “creates to me the urgency to check our assumptions to make sure that in light of different opinions from the analysts, we are correct or not. So we have done that repeatedly and we came to the conclusion that we tell you that we expect to have a high single digit from ‘28 to ‘33. And we know very well where are the discrepancies between the products.” The discrepancies run past pipeline coverage — “there are not only on the pipeline, which many analysts, they do not cover. So you have the phenomenon that from 12, 13 analysts that are forming the overall performance of the year [transcript garble], for some products, only 5 analysts, they have this one and the others they don’t” — but reach launched products too, and he named two “that I think people need to reevaluate their assessment.” On NURTEC: “we are already close to $2 billion… if you annualize it, and the Street has us almost $2.5 billion by year 2030. So I think there is a discrepancy there.” On the elranatamab field (the tape’s “ELRex” — elranatamab with a competing product unnamed here): “the Street is forecasting $5 billion and for us $600 million. We aspire to present a profile that is very similar in efficacy and better in tolerability and in side effects. Now, remains to be proven, but I don’t think that $600 million vis-à-vis $5 billion, it is justifiable, even with the current information.” The conversion thesis: “as more information is coming for our pipeline and readouts… the Street probably will start adjusting their numbers and there will be a conversion, possibly.”
The “Analyst’s Take”: Cecile delivered a roadmap rather than a rebuff — dates, named LOE products, an 18-to-24-month catalyst arc — but skipped both the philosophy benchmark and product-level numbers, while Bourla’s addendum was the only exchange of the session naming per-product revenue with the Street’s figures attached directly beside them (two named uploads on the same board: NURTEC and the elranatamab competitor), both quantified and both actionable for a modeling refresh. The “possibly” at the end does quiet work: the collision is forecast, not promised. The two halves read coordinated — qualitative architecture from the CFO, falsifiable product-level bets from the CEO — consistent with the closing posture: the Street is being handed a homework list, not a bridge.

Synthesis

Clusters

Concern	Analysts (Q#s)	Uniform management answer	Signal
Berobenatide / amylin readout timing and data integrity	Schott (Q1b), Tiwari (Q5b), Meacham (Q11b), Hammond (Q12a)	SOLIS-1 fully recruited, Phase 2b efficacy readout in 2H-2027; Phase 1/2a is a safety-and-PK study with an end-2026 update and “nothing material changed”; obesity goal: potentially best-in-class monthly subcutaneous GLP-1, with knee-OA and OSA ± PAP studies starting and more Phase 3 announcements coming	One story told four ways: management is walling the Phase 1/2a off from efficacy expectations ahead of the readout year
MEVPRO cadence and formulation	Scala (Q8a), Q9 follow-up, Q10 clarification, Yee (Q14a)	Event-driven studies; MEVPRO-1 Q1-2027 with a February anchor, MEVPRO-2 corrected to Q4-2027 per the trial registry; Phase 3 formulation with food, lower Cmax, similar AUC to Phase 1	The cadence is stable but the quarter is in flux — management corrects itself against the public record live
Capital allocation through the LOE wall	Rafat (Q4), Seigerman (Q7), Haider (Q15a)	Priorities unchanged: invest for growth, maintain or grow the dividend, keep a strong balance sheet; through LOE the funding stack is operating cash flow plus financial assets plus capital-markets access; buybacks “become again one of the levers” post-LOE	Three separately worded questions get one framework: dividends funded today, repurchases parked
Trispecific positioning and the derm franchise	Schott (Q1a), Q2 follow-up, Yee (Q14b)	Phase 3 in AD underway including a head-to-head against dupilumab; positioning = lapsed/naive capture on a defined profile (first-in-class, strong efficacy, unmet need); no functional ADAs to date	AD positioning trades today’s entry angle for a post-readout profile — the commercial thesis is built around a franchise pattern, not a first claim

Deflections

Topic (Q#)	What was asked	Deflection technique
2027 guidance specifics (Q3, Q15)	Quantified US net-price, IRA/MFP, 340B, MFN effects for 2027	Calendar gate: “not commenting today on 2027” — qualitative drivers offered, numbers deferred to mid-December
Marginal-dollar ranking (Q7)	Highest prospective return across R&D / bolt-on / BD / deleveraging / buybacks	List without ranking: priorities restated, sequencing implied (post-LOE), no preferred next dollar named
Big-deal appetite (Q8b)	Why not make another big deal the primary focus	Reframe plus premise correction: deals cited are ones already executed; future BD narrowed to bolt-ons inside the four TAs
Guidance philosophy vs predecessor (Q15a)	How her guidance philosophy compares to Dave’s	Non-engagement: the sub-question is simply not picked up
Dropout data (Q14a)	How dropouts respond to the formulation change	Status affirmation: confidence in dose and PK; dropouts left unspoken
TARC-versus-degraders comparison (Q5a)	Biochemical positioning of STAT6 against competitor degraders	Redirection to the schedule: program adapted with DDI studies, readout dated, comparison unopened

Contradictions

Contradiction	Prepared-remarks claim (source in transcript)	Q&A walk-back
MEVPRO-2 readout timing	Prepared remarks date only the MEVPRO-1 readout — “a readout from MEPHRO-1, which based on the current event rate is now expected in the first quarter of 2027” (script para on MEVPRO)	In Q9 the answer states MEVPRO-2 as Q3-2027 and then, within the same answer, corrects to “just to correct, MEVRO-2 is actually Q4 2027, the updated in clinicaltrials.gov”
The analyst’s trispecific label	Prepared remarks establish telrecomec as Pfizer’s trispecific (script para on telrecomec)	Q14 names it “teclistamab” — a Johnson & Johnson-marketed bispecific; management’s answer re-keys to the actual asset without confronting the mislabel
Flat OpEx vs savings on track	Prepared remarks tout phase-1 savings on track — $7.2B, nearly all delivered by end-2026 (script para on the cost programs)	Q4 puts the premise forward (analyst-provided $24.5B 2022 ≈ 2026 OpEx); management does not dispute the arithmetic, instead recontextualizing savings placement (manufacturing footprint, R&D reinvested) and citing Q3 one-time SG&A dynamics

Unanswered

Q1(b): titration schedules for the SOLIS-1 arms — described only as “different doses and different titrations.”
Q3: Q3 340B “scrubbing” not quantified — answered only at the level of “no very material change” to quarter GTN.
Q4: no terminal-year OpEx level given — only a FY26 SG&A direction and a 2027–2029 mitigant.
Q5(a): the TARC-reduction-vs-degraders comparison never taken up.
Q7: marginal-dollar ranking across R&D / BD / deleveraging / buybacks not ranked.
Q8(a): no timeline offered for MEVPRO-3.
Q11(a): scrutiny of prior OUS agreements passed over in the tariff/MFN stability framing.
Q12(a): no OUS launch plan stated for berobenatide itself — strategy confirmation only.
Q12(b): no FDA-vs-EMA differences enumerated — only a Canada filing and a Q4-2026 FDA update promised.
Q14(a): dropout experience under the reformulated Phase 3 dose left unspoken.
Q15(a): guidance-philosophy benchmark versus Dave not taken up.